Get the Stockscreener App
0.2706
0.56%
0.0015
After Hours:
.27
-0.0006
-0.22%
Calidi Biotherapeutics Inc stock is traded at $0.2706, with a volume of 5.35M.
It is up +0.56% in the last 24 hours and down -14.93% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.2691
Open:
$0.272
24h Volume:
5.35M
Relative Volume:
12.89
Market Cap:
$2.95M
Revenue:
-
Net Income/Loss:
$-25.74M
P/E Ratio:
-0.0548
EPS:
-4.938
Net Cash Flow:
$-21.41M
1W Performance:
+8.98%
1M Performance:
-14.93%
6M Performance:
-83.70%
1Y Performance:
-95.35%
1-Day Range:
$0.258
$0.2958
1-Week Range:
$0.2509
$0.2982
52-Week Range:
$0.2088
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.2706 | 2.93M | 0 | -25.74M | -21.41M | -4.938 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics to Showcase Advances in Virotherapy at RedChip's Virtual Investor Conference on April 16, 2026 - Quiver Quantitative
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor ... - Caledonian Record
Calidi to present RedTail platform data at Iceland conference By Investing.com - Investing.com Canada
Calidi to present RedTail platform data at Iceland conference - Investing.com
Cancer virus therapy data from Calidi heads to Iceland conference - Stock Titan
Fed Watch: Does Calidi Biotherapeutics Inc have pricing powerFed Meeting & AI Based Buy and Sell Signals - baoquankhu1.vn
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Does Calidi Biotherapeutics Inc have pricing power2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Calidi Biotherapeutics (CLDI) Stock Analysis Report | Financials & Insights - Benzinga España
Calidi Biotherapeutics, Inc. (CLDI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Sahm
Aug Shorts: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Trend Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Calidi Biotherapeutics Announces Speaker Presentation At ASGCT and Highlighting the Redtail Platform?s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - marketscreener.com
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Bitget
Calidi takes tumor-targeting gene therapy data to Boston, eyes 2026 IND - Stock Titan
Sell Signal: Is Calidi Biotherapeutics Inc subject to activist investor interestOptions Play & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Calidi Biotherapeutics to reduce board size as director term nears expiration By Investing.com - Investing.com Australia
Calidi Biotherapeutics to reduce board size as director term nears expiration - Investing.com Canada
Calidi Biotherapeutics (CLDI) Hinges on High-Stakes Q4 2026 IND Filing as Market Waits for Catalyst - Bitget
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks
Allan Camaisa to Leave Calidi Board; Scott Leftwich Joins Audit Committee - TradingView
Director transition leads Calidi Biotherapeutics (CLDI) to cut board size to five - Stock Titan
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - The Manila Times
Calidi tees up new cancer-virus data before planned 2026 IND filing - Stock Titan
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Sahm
CLDI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Calidi brings tumor-targeted immune therapy data to cancer meeting - Stock Titan
Investor in Calidi Biotherapeutics (CLDI) discloses 0.3% stake - Stock Titan
VIX Spike: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Inflation Data: Is Calidi Biotherapeutics Inc forming a breakout pattern2026 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Calidi Biotherapeutics Reports 2025 Financial Results, Advances CLD-401 Clinical Development and Expands RedTail Platform Partnerships - Minichart
Calidi Biotherapeutics, Inc. 2025 Annual 10-K Report Highlights Equity, Warrants, and Financial Arrangements - Minichart
Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline - TipRanks
Calidi 2025 10-K: $20.24M operating loss, $20.06M net loss, $5.6M cash - TradingView
Calidi Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Calidi Biotherapeutics (CLDI) 10-K shows going-concern risk and early oncology pipeline - stocktitan.net
Calidi Biotherapeutics (NYSE: CLDI) reports 2025 loss and $5.6M cash - stocktitan.net
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - Bitget
Calidi Biotherapeutics released its financial results for the fourth quarter and full year of 2025, along with an update on its recent operational progress. - bitget.com
CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch - Intellectia AI
Market Pulse: Will Calidi Biotherapeutics Inc benefit from sector rotation2026 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Gap Down: Should I hold or sell Calidi Biotherapeutics Inc nowMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials - The Manila Times
Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval - TradingView
Calidi Biotherapeutics Announces Partnership with Avance - GlobeNewswire
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
Calidi Biotherapeutics prices $5.2M underwritten public offering - MSN
Big Picture: Can Calidi Biotherapeutics Inc keep up with sector leaders2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Cap:
|
Volume (24h):